Paul Sakuma, Associated Press
SALT LAKE CITY — Utah will get $8.5 million from GlaxoSmithKline for defrauding the state’s Medicaid program through allegedly false and misleading marketing of Avandia.
GSK introduced Avandia in 1999 as a new diabetic medication to treat Type 2 diabetes by helping sensitize cells to insulin and thereby assisting in blood-sugar control.
The Medicaid Fraud Control Unit of the attorney general’s office filed the lawsuit in 2010 and alleged GSK marketed Avandia nationwide as a “wonder drug” and as a “significant advance” in diabetes treatment.
The lawsuit also alleged Avandia has been proven to increase the risk of cardiovascular events, including heart attacks, among certain users of Avandia.
“This settlement is a great outcome in a complex case,” said Robert Steed, director of the Medicaid fraud unit.
— Dennis Romboy
- Author, activist speaks at Theodore Roosevelt...
- Man accused of killing UTA worker dies in prison
- Women underrepresented across Utah's...
- Mike Lee, US Senate to hold monument meeting...
- 7 tips for summer travel while pregnant
- Pleasant View fire contained Saturday;...
- Utah Democrats headed to 'historic' national...
- Holladay woman dies rock climbing in Maple...
- Planned Parenthood 'CTR' campaign draws... 64
- New rule sparks debate over teacher... 48
- Utah Democrats headed to 'historic'... 29
- Utah Democrat: Kaine 'kind of person we... 22
- San Juan County residents say 'doodah'... 19
- Utah Democrats see opportunity in... 17
- Two Utah schools under federal... 13
- Sanders urges Utah and other... 13